Skip to main
VNRX
VNRX logo

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 88%
Buy 13%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd is positioned for growth in the pharmaco-epigenetics space due to ongoing collaborations and partnerships, which could enhance revenue and facilitate the adoption of its biomarker technology. The validation of the Nu.Q Lung Cancer Test is expected to de-risk the technology and attract strategic partnerships, further solidifying its appeal within the diagnostics market. Additionally, the introduction of an automated system in veterinary diagnostics and the successful adoption of Nu.Q Discover biomarkers in over 1,000 veterinary hospitals in Japan indicate a strong market interest and a potential increase in revenue capacity for the company.

Bears say

VolitionRX Ltd's focus on developing blood tests using its Nucleosomics platform faces financial challenges, particularly due to the ongoing issues related to high false-positive rates in lung cancer screenings, which may undermine the reliability of its diagnostic tests. The company's financial performance is potentially jeopardized as the need for further validation studies may delay commercialization and increase costs, impacting revenue generation. Additionally, the reliance on clinical studies to validate its products can result in significant uncertainty regarding future cash flows and overall market acceptance, thus placing strain on investor confidence and stock performance.

Volitionrx Limited (VNRX) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 88% of analysts recommend a Strong Buy, 13% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.